Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03781752 · ClinicalTrials.gov registry record · Phase 4
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
A Phase 4 study of Attention Deficit Hyperactivity Disorder and ADHD, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 500
- Enrollment target
- 4
- Study locations
NCT03781752 is a Phase 4 study of Attention Deficit Hyperactivity Disorder and ADHD that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 500 participants, above the 201-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (149% higher). The trial reports 4 study locations across 4 states.
The verdict
NCT03781752, a Phase 4 study of Attention Deficit Hyperactivity Disorder and ADHD, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 500 participants
- Enrollment target
- 4
- Study locations
Study Summary
The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
Conditions Studied
Interventions
- DRUG Methylphenidate
Study Locations (4)
Florida
- University of Florida - Gainesville
New York
- Icahn School of Medicine at Mount Sinai - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2018-03-04 |
| Est. Completion | 2025-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03781752
The ClinicalTrials.gov registry entry for NCT03781752 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 201-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (149% higher). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which Methylphenidate is the first listed.
NCT03781752 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT03781752 about?
NCT03781752 is a clinical study titled "Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD". The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
What is the current status of trial NCT03781752?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 500 participants. The study started on 2018-03-04. Estimated completion is 2025-08.
What conditions does trial NCT03781752 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder, ADHD.
What interventions are being tested in trial NCT03781752?
The interventions under investigation include: Methylphenidate (DRUG).
Who is sponsoring clinical trial NCT03781752?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03781752 being conducted?
This trial has 4 study locations across Florida, New York, Ohio, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
RECRUITING · Phase 4
-
R61/33 - VR Study Phase 4
RECRUITING · Phase 4
-
A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
RECRUITING · Phase 4
-
Stimulant Effects on Disruptive Behavior
RECRUITING · Phase 4
-
Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate
COMPLETED · Phase 4
-
A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.